Pipeline update from Ocuphire

Bindu Manne, lead of Market Development at Ocuphire, sat down with Optometry Times during the 2022 American Academy of Optometry meeting held in San Diego to give a company update.

Editor's note: This transcript has been edited for clarity.

Hello, I'm Bindu Manne. I lead Market Development here at Ocuphire. The Ocuphire team is thrilled to be here at this year's American Academy of Optometry meeting in beautiful, sunny San Diego.

Our core strand here at Ocuphire has been generating high-quality data and presenting that information to the medical community. We're thrilled to have six poster presentations on both Nyxol and APX3330. We're presenting data from all of our clinical programs. So Mira for reversal mydriasis, Vega for presbyopia, Lynx for night vision disturbance or NBD, and Apex 3330 or Zeta study for diabetic retinopathy.

In addition to our clinical presentation, scientific presentations, we are engaging the thought leaders as well in part of our market development or pre-commercial activities. We want to understand the pain points associated with dilations and the potential opportunity for a reversal agent, what that means to their patients and their practices.

In addition to that, we're also learning more about the presbyopia space from our thought leaders. Their excitement for the space, the pharmacologic management of presbyopia, remains high and we're pleased to hear that information as well. So we hope to bring innovative products into the market in the future, and thrilled to be here.